Crossmark Global Holdings, Inc. Biogen Inc. Transaction History

Crossmark Global Holdings, Inc.

$5.61 Billion
Q3 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 7,057 shares of BIIB stock, worth $1.04 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

7,057

Previous 7,451 5.29%

Holding current value

$1.04 Million

Previous $1.73 Million 20.85%

% of portfolio

0.02%

Previous 0.03%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$189.07 - $236.8 $74,493 - $93,299	-394 Reduced 5.29%	7,057 $1.37 Million
Q2 2024 Jul 29, 2024	SELL	$190.52 - $236.72 $344,269 - $427,753	-1,807 Reduced 19.52%	7,451 $1.73 Million
Q1 2024 May 13, 2024	SELL	$212.02 - $267.71 $57,033 - $72,013	-269 Reduced 2.82%	9,258 $2 Million
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $501,940 - $604,204	-2,255 Reduced 19.14%	9,527 $2.47 Million
Q3 2023 Nov 08, 2023	SELL	$253.3 - $285.89 $2.85 Million - $3.22 Million	-11,265 Reduced 48.88%	11,782 $3.11 Million
Q2 2023 Jul 31, 2023	SELL	$275.25 - $318.06 $229,833 - $265,580	-835 Reduced 3.5%	23,047 $6.11 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $182,670 - $208,146	712 Added 3.07%	23,882 $6.64 Million
Q4 2022 Jan 19, 2023	BUY	$252.44 - $306.72 $1.16 Million - $1.41 Million	4,602 Added 24.78%	23,170 $6.42 Million
Q3 2022 Nov 01, 2022	BUY	$194.69 - $268.46 $136,088 - $187,653	699 Added 3.91%	18,568 $4.96 Million
Q2 2022 Jul 29, 2022	SELL	$187.54 - $223.02 $59,825 - $71,143	-319 Reduced 1.75%	17,869 $3.64 Million
Q1 2022 May 11, 2022	BUY	$193.77 - $244.14 $1.1 Million - $1.39 Million	5,687 Added 45.49%	18,188 $3.83 Million
Q4 2021 Jan 10, 2022	BUY	$223.92 - $287.77 $572,115 - $735,252	2,555 Added 25.69%	12,501 $3 Million
Q3 2021 Oct 21, 2021	BUY	$282.99 - $369.05 $602,485 - $785,707	2,129 Added 27.24%	9,946 $2.82 Million
Q3 2021 Oct 13, 2021	SELL	$282.99 - $369.05 $253,842 - $331,037	-897 Reduced 10.29%	7,817 $1.17 Million
Q2 2021 Jul 21, 2021	SELL	$259.0 - $414.71 $355,089 - $568,567	-1,371 Reduced 13.59%	8,714 $3.02 Million
Q1 2021 Apr 15, 2021	SELL	$242.95 - $284.63 $153,544 - $179,886	-632 Reduced 5.9%	10,085 $2.82 Million
Q4 2020 Jan 14, 2021	BUY	$236.26 - $355.63 $46,070 - $69,347	195 Added 1.85%	10,717 $2.62 Million
Q3 2020 Oct 08, 2020	SELL	$264.77 - $305.71 $46,864 - $54,110	-177 Reduced 1.65%	10,522 $2.99 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $174,595 - $231,221	-675 Reduced 5.93%	10,699 $2.86 Million
Q1 2020 Apr 28, 2020	SELL	$268.85 - $341.04 $124,208 - $157,560	-462 Reduced 3.9%	11,374 $3.6 Million
Q4 2019 Feb 06, 2020	SELL	$220.06 - $304.07 $507,678 - $701,489	-2,307 Reduced 16.31%	11,836 $3.51 Million
Q3 2019 Oct 09, 2019	SELL	$217.44 - $243.88 $209,394 - $234,856	-963 Reduced 6.37%	14,143 $3.29 Million
Q2 2019 Jul 09, 2019	BUY	$219.29 - $241.72 $207,448 - $228,667	946 Added 6.68%	15,106 $3.53 Million
Q1 2019 May 02, 2019	SELL	$216.71 - $338.96 $61,979 - $96,942	-286 Reduced 1.98%	14,160 $3.35 Million
Q4 2018 Jan 31, 2019	BUY	$278.5 - $352.75 $206,925 - $262,093	743 Added 5.42%	14,446 $4.35 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $304,369 - $398,031	-1,037 Reduced 7.04%	13,703 $4.84 Million
Q2 2018 Jul 31, 2018	SELL	$257.52 - $306.91 $439,329 - $523,588	-1,706 Reduced 10.37%	14,740 $4.28 Million
Q1 2018 Apr 16, 2018	BUY	$260.13 - $367.91 $275,477 - $389,616	1,059 Added 6.88%	16,446 $4.5 Million
Q4 2017 Feb 05, 2018	SELL	$307.64 - $344.58 $348,556 - $390,409	-1,133 Reduced 6.86%	15,387 $4.9 Million
Q3 2016 Oct 25, 2017	BUY	N/A	16,520	16,520 $5.17 Million

Others Institutions Holding BIIB

# of Institutions

1,038

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Biogen Inc. Transaction History